Back

Serotonin 5-HT2C receptor as a cellular target of PI3K inhibitor LY294002 and its analog LY303511

Kotova, P. D.; Dymova, E. A.; Lyamin, O. O.; Rogachevskaja, O. A.; Voronova, E. A.; Kolesnikov, S. S.

2025-11-08 pharmacology and toxicology
10.1101/2025.11.06.687025 bioRxiv
Show abstract

The inhibitory analysis of intracellular signaling pathways is widely employed to gain insight into molecular mechanisms underlying diverse physiological processes. Unfortunately, the essential drawback of this basically effective methodology is that many, if not all, inhibitors, antagonists, modulators, and blockers can affect cellular functions not only acting through specified cellular targets, but also causing off-target effects. In particular, the class I phosphatidylinositol-3-kinase (PI3K) inhibitor LY294002 and its PI3K-inactive structural analog LY303511 have been shown to affect agonist-induced Ca2+ signaling in cells of various types independently of PI3K activity. Here we studied serotonin-induced Ca2+ signaling in HEK293 cells expressing the recombinant mouse 5-HT2C receptor and analyzed the effects of LY294002 and LY303511 on cell responsiveness. As shown with Ca2+ imaging, both LY294002 and LY303511 affected intracellular Ca2+ but via distinct mechanisms. LY294002 suppressed responsiveness of assayed cells to serotonin in a manner suggesting that this substance acted as a competitive antagonist of the 5-HT2C receptor. In turn, LY303511 itself triggered Ca2+ transients in 5-HT2C-positive cells, exhibiting traits of a 5-HT2C agonist. In support of these findings, molecular docking and molecular dynamics simulations validated the binding of both LY294002 and LY303511 to the 5-HT2C receptor and occupying its orthosteric site. Altogether, physiological findings and computational data suggested that the observed effects of these compounds were most likely mediated by extracellular mechanisms associated with the direct interaction of both with the 5-HT2C receptor. This expands the list of non-specified cellular targets of LY294002 and LY303511 with 5-HT2C subtype of serotonin receptors.

Matching journals

The top 4 journals account for 50% of the predicted probability mass.

1
ACS Pharmacology & Translational Science
40 papers in training set
Top 0.1%
23.0%
2
British Journal of Pharmacology
34 papers in training set
Top 0.1%
15.1%
3
Frontiers in Pharmacology
100 papers in training set
Top 0.2%
10.7%
4
Biochemical Pharmacology
18 papers in training set
Top 0.1%
7.0%
50% of probability mass above
5
Scientific Reports
3102 papers in training set
Top 22%
5.0%
6
Neuropharmacology
60 papers in training set
Top 0.2%
5.0%
7
ACS Chemical Neuroscience
60 papers in training set
Top 0.4%
4.4%
8
International Journal of Molecular Sciences
453 papers in training set
Top 2%
3.7%
9
The Journal of Pharmacology and Experimental Therapeutics
15 papers in training set
Top 0.1%
2.1%
10
Molecular Pharmacology
15 papers in training set
Top 0.1%
1.9%
11
European Journal of Pharmacology
11 papers in training set
Top 0.2%
1.3%
12
Pharmaceuticals
33 papers in training set
Top 1.0%
1.3%
13
eLife
5422 papers in training set
Top 51%
1.0%
14
PLOS ONE
4510 papers in training set
Top 64%
0.9%
15
Neuropsychopharmacology
134 papers in training set
Top 2%
0.9%
16
Cellular and Molecular Life Sciences
84 papers in training set
Top 0.5%
0.8%
17
PLOS Computational Biology
1633 papers in training set
Top 24%
0.8%
18
Biomedicine & Pharmacotherapy
43 papers in training set
Top 1%
0.8%
19
Biochimica et Biophysica Acta (BBA) - General Subjects
16 papers in training set
Top 0.2%
0.8%
20
Neurotherapeutics
11 papers in training set
Top 0.5%
0.8%
21
ACS Omega
90 papers in training set
Top 5%
0.7%
22
Journal of Biological Chemistry
641 papers in training set
Top 6%
0.5%
23
Genes to Cells
23 papers in training set
Top 0.4%
0.5%